Ascletis Pharma Stock Performance
| ASCLF Stock | USD 0.18 0.00 0.00% |
On a scale of 0 to 100, Ascletis Pharma holds a performance score of 7. The firm shows a Beta (market volatility) of 1.83, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ascletis Pharma will likely underperform. Please check Ascletis Pharma's coefficient of variation and the relationship between the information ratio and day median price , to make a quick decision on whether Ascletis Pharma's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Ascletis Pharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Ascletis Pharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.2 B | |
| Total Cashflows From Investing Activities | -274.5 M |
Ascletis |
Ascletis Pharma Relative Risk vs. Return Landscape
If you would invest 15.00 in Ascletis Pharma on August 30, 2024 and sell it today you would earn a total of 3.00 from holding Ascletis Pharma or generate 20.0% return on investment over 90 days. Ascletis Pharma is currently producing 0.3562% returns and takes up 3.7478% volatility of returns over 90 trading days. Put another way, 33% of traded pink sheets are less volatile than Ascletis, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Ascletis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascletis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Ascletis Pharma, and traders can use it to determine the average amount a Ascletis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.095
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ASCLF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.75 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Ascletis Pharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascletis Pharma by adding it to a well-diversified portfolio.
Ascletis Pharma Fundamentals Growth
Ascletis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Ascletis Pharma, and Ascletis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascletis Pink Sheet performance.
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X | |||
| Revenue | 76.88 M | |||
| EBITDA | (169.35 M) | |||
| Cash And Equivalents | 2.5 B | |||
| Cash Per Share | 2.28 X | |||
| Total Debt | 2.75 M | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (146.93 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 2.83 B | |||
About Ascletis Pharma Performance
By analyzing Ascletis Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascletis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascletis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascletis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer ASC61 and ASC63 for advanced solid tumors ASC60 to treat solid tumors and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the Peoples Republic of China. Ascletis Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 266 people.Things to note about Ascletis Pharma performance evaluation
Checking the ongoing alerts about Ascletis Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Ascletis Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascletis Pharma has some characteristics of a very speculative penny stock | |
| Ascletis Pharma had very high historical volatility over the last 90 days | |
| Ascletis Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 76.88 M. Net Loss for the year was (199.02 M) with profit before overhead, payroll, taxes, and interest of 39.17 M. | |
| Ascletis Pharma has accumulated about 2.5 B in cash with (146.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 67.0% of the company shares are held by company insiders |
- Analyzing Ascletis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascletis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascletis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascletis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascletis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascletis Pharma's pink sheet. These opinions can provide insight into Ascletis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascletis Pink Sheet analysis
When running Ascletis Pharma's price analysis, check to measure Ascletis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascletis Pharma is operating at the current time. Most of Ascletis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascletis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascletis Pharma's price. Additionally, you may evaluate how the addition of Ascletis Pharma to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |